Hepatitis C: Clinical Trials

389 trials for Hepatitis C, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

389 completed. 389 Phase 2, 40 Phase 1, 31 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2389Completed 389
Phase 140Completed 40
Phase 331Completed 31

Follow Hepatitis C: new trials by email Literature Review of Hepatitis C trials Research Report on Hepatitis C

Trials (filtered) newest first · largest first

All 389 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic
Phase 2CompletedAtea Pharmaceuticals, Inc.2752023-05-302025-10-21
Glecaprevir/Pibrentasvir for the Treatment of PTSD
Glecaprevir / Pibrentasvir Pill - PTSD
Phase 2 / Phase 3CompletedWhite River Junction Veterans Affairs Medical Center102023-04-012024-08-29
Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone
MTL-CEBPA, Sorafenib - Hepatocellular Carcinoma, Hepatitis B
Phase 2CompletedMina Alpha Limited82022-01-012025-03-06
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
glecaprevir/pibrentasvir (GLE/PIB) - Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Phase 1 / Phase 2CompletedUniversity of California, San Diego122021-05-282022-05-24
8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C
Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C
Phase 2 / Phase 3CompletedMuhammad Radzi Abu Hassan3222021-03-232025-03-13
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
HEC110114 Tablet, Sofosbuvir Tablet - Chronic Hepatitis C
Phase 1 / Phase 2CompletedSunshine Lake Pharma Co., Ltd.242020-07-062020-09-10
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Glecaprevir/Pibrentasvir (G/P) - Hepatitis C Infection, HIV Infection
Phase 2CompletedAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections452019-11-202024-07-11
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
sofosbuvir/velpatasvir - Liver Transplant, Hepatitis C
Phase 2CompletedFernanda P Silveira, MD, MS52019-08-152026-04-30
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic
Phase 2CompletedAtea Pharmaceuticals, Inc.102019-06-202020-05-04
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
Sofosbuvir and Velpatasvir - Hepatitis C, Acute Hepatitis C
Phase 2CompletedHannover Medical School202019-05-282021-07-06
Utilization of Hepatitis C Positive Kidneys in Negative Recipients
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C
Phase 2 / Phase 3CompletedOhio State University542019-03-222023-09-13
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
Ledipasvir / Sofosbuvir Oral Product - Hepatitis C, Chronic, Hematologic Malignancy
Phase 1 / Phase 2CompletedAin Shams University242019-03-012023-08-22
Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis
PRI-724 - Hepatitis C, Hepatitis B
Phase 1 / Phase 2CompletedKiminori Kimura, MD272018-07-242024-10-10
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
CDI-31244, SOF/VEL - Chronic Hepatitis C
Phase 2CompletedCocrystal Pharma, Inc.122018-06-262021-04-28
A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Mavyret - Hepatitis C
Phase 2CompletedNYU Langone Health202018-05-122021-09-05
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin, non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin, non-cirrhotic subjects. low TG-2349+ low DAG181 - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
Phase 2CompletedDongguan HEC TaiGen Biopharmaceuticals Co., Ltd.1332018-03-152021-02-18
Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children
Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet - Hepatitis C, Chronic
Phase 2CompletedMansoura University Children Hospital502018-03-012021-10-25
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic
Phase 2 / Phase 3CompletedJohns Hopkins Bloomberg School of Public Health1502018-02-022021-05-18
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
EBR/GZR FDC Tablet, Placebo, Grazoprevir Oral Granules - HCV Infection
Phase 2CompletedMerck Sharp & Dohme LLC572018-01-252023-05-31
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG - Hepatitis C
Phase 2CompletedUniversity of Dundee1292018-01-192021-11-18

Showing 20 of 389. Sign in to see all of them.

Narrower conditions

Hepatitis C, Chronic (194)  ·  HIV Infections (24)  ·  Hepatitis (21)  ·  Fibrosis (15)  ·  Liver Diseases (15)  ·  Liver Cirrhosis (11)  ·  Virus Diseases (8)  ·  Hepatitis, Chronic (7)  ·  Bronchiolitis Obliterans Syndrome (5)  ·  Carcinoma, Hepatocellular (5)  ·  Hepatitis B (5)  ·  Coinfection (4)  ·  Infections (4)  ·  Acquired Immunodeficiency Syndrome (3)

Broader conditions

Blood-Borne Infections (389)  ·  Communicable Diseases (388)  ·  Digestive System Diseases (387)  ·  Flaviviridae Infections (387)  ·  Hepatitis, Viral, Human (387)  ·  RNA Virus Infections (386)  ·  Infections (385)  ·  Virus Diseases (381)  ·  Liver Diseases (374)  ·  Hepatitis (368)  ·  Pathological Conditions, Signs and Symptoms (216)  ·  Pathologic Processes (215)  ·  Disease Attributes (199)  ·  Chronic Disease (198)  ·  Hepatitis, Chronic (191)

Interventions

Ribavirin (198)  ·  peginterferon alfa-2a (94)  ·  Sofosbuvir (45)  ·  daclatasvir (26)  ·  peginterferon alfa-2b (26)  ·  Ritonavir (22)  ·  ledipasvir, sofosbuvir drug combination (22)  ·  Simeprevir (19)  ·  grazoprevir (17)  ·  paritaprevir (17)  ·  sofosbuvir-velpatasvir drug combination (17)  ·  telaprevir (17)  ·  ombitasvir (15)  ·  elbasvir (12)  ·  dasabuvir (11)

Sponsors

Gilead Sciences (50)  ·  Merck Sharp & Dohme LLC (35)  ·  Bristol-Myers Squibb (23)  ·  Hoffmann-La Roche (16)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (15)  ·  AbbVie (14)  ·  Vertex Pharmaceuticals Incorporated (13)  ·  AbbVie (prior sponsor, Abbott) (11)  ·  ANRS, Emerging Infectious Diseases (10)  ·  Boehringer Ingelheim (9)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8)  ·  Romark Laboratories L.C. (6)  ·  French National Agency for Research on AIDS and Viral Hepatitis (5)  ·  Conatus Pharmaceuticals Inc. (4)  ·  Debiopharm International SA (4)

Countries

United States (205)  ·  France (67)  ·  Puerto Rico (65)  ·  Germany (62)  ·  Canada (42)  ·  Spain (38)  ·  United Kingdom (35)  ·  Australia (31)  ·  New Zealand (29)  ·  Belgium (27)  ·  Italy (24)  ·  Poland (21)  ·  Austria (18)  ·  Egypt (13)  ·  Japan (12)

Top investigators

Asem Elfert, MD (4)  ·  Daniel Cohen, MD (4)  ·  Robert H. Hyland, DPhil (4)

Results publications

PMID 28193518, PMID 30012435, PMID 30923816, PMID 30977945, PMID 24154738, PMID 24209977, PMID 24983020, PMID 25164700, PMID 25445400, PMID 25830171, PMID 26596948, PMID 26683763, PMID 26691547, PMID 26752189, PMID 28412293, PMID 28802814, PMID 28802816, PMID 31568620, PMID 15282352, PMID 15316341, PMID 15374882, PMID 15563253, PMID 15667486, PMID 15685543, PMID 15820563, PMID 15867490, PMID 16115185, PMID 16439867, PMID 16544259, PMID 16987047, PMID 17058240, PMID 17147494, PMID 17200799, PMID 17263626, PMID 17582705, PMID 17721093, PMID 17721100, PMID 18184077, PMID 18435468, PMID 18666223, PMID 18771667, PMID 19268724, PMID 19403902, PMID 19403903, PMID 19447518, PMID 19594300, PMID 19797971, PMID 19852040, PMID 19898214, PMID 20375406

NIH funding

2014 (12), 2009 (8), 2015 (8), 2016 (7), 2008 (4), 2004 (2), R01DA026727 (2), 2005 (1), 2017 (1), 2018 (1), 2019 (1), N01CN35160 (1), P50AT000009 (1), R01AI049141 (1), R01AI049508 (1)